CYP2C19基因多态性与缺血性脑血管病支架术后缺血性事件的相关性研究(3)
[2] Xie X，Ma YT，Yang YN，et al.Personalized antiplatelet therapy according to cyp2c19 genotype after percutaneous coronary intervention： A randomized control trial[J].Int J Cardiol， 2013， 168(4)： 3736-3740.
[3] Simon T，Verstuyft C，Mary-Krause M，et al.Genetic determ inants of response to clopidogrel and cardiovascular events[J].N Engl J Med，2009，360(4)：363-375.
[4] Shuldiner AR， O'Connell JR， Bliden KP，et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA，2009，302(8)：849-857.
[5] Barker CM， Murray SS， Teirstein PS， et al. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to cyp2c19 genotype in patients with high on-treatment reactivity[J].JACC Cardiovasc Interv， 2010(3)：1001-1007.
[6] Pan Y， Chen W， Xu Y， et al.Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack： A Systematic Review and Meta-Analysis[J].Circulation，2017，135(1)：21-33.
[7] U.S. Food and Drug Administration.FDA Drug Safety Communication： Reduced effectiveness of plavix(clopidogrel) in patients who are poor metabolizers of the drug[EB/OL].http： / /www. fda. gov /Drugs，2010-03-12.
[8] 董靖德，靳凌，張丽.CYP2C19基因多态性对颈动脉支架植入术后支架内血栓形成的影响[J].实用老年医学，2016， 30(8)：676-682.
(收稿日期：2017-01-23), 百拇医药(阳清伟 陈星宇 陈良义)
[3] Simon T，Verstuyft C，Mary-Krause M，et al.Genetic determ inants of response to clopidogrel and cardiovascular events[J].N Engl J Med，2009，360(4)：363-375.
[4] Shuldiner AR， O'Connell JR， Bliden KP，et al.Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[J].JAMA，2009，302(8)：849-857.
[5] Barker CM， Murray SS， Teirstein PS， et al. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to cyp2c19 genotype in patients with high on-treatment reactivity[J].JACC Cardiovasc Interv， 2010(3)：1001-1007.
[6] Pan Y， Chen W， Xu Y， et al.Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack： A Systematic Review and Meta-Analysis[J].Circulation，2017，135(1)：21-33.
[7] U.S. Food and Drug Administration.FDA Drug Safety Communication： Reduced effectiveness of plavix(clopidogrel) in patients who are poor metabolizers of the drug[EB/OL].http： / /www. fda. gov /Drugs，2010-03-12.
[8] 董靖德，靳凌，張丽.CYP2C19基因多态性对颈动脉支架植入术后支架内血栓形成的影响[J].实用老年医学，2016， 30(8)：676-682.
(收稿日期：2017-01-23), 百拇医药(阳清伟 陈星宇 陈良义)